JP2023544732A5 - - Google Patents
Info
- Publication number
- JP2023544732A5 JP2023544732A5 JP2023520101A JP2023520101A JP2023544732A5 JP 2023544732 A5 JP2023544732 A5 JP 2023544732A5 JP 2023520101 A JP2023520101 A JP 2023520101A JP 2023520101 A JP2023520101 A JP 2023520101A JP 2023544732 A5 JP2023544732 A5 JP 2023544732A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- salt
- fibrosis
- disease
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086726P | 2020-10-02 | 2020-10-02 | |
| US63/086,726 | 2020-10-02 | ||
| PCT/US2021/052897 WO2022072647A1 (en) | 2020-10-02 | 2021-09-30 | Imidazopiperazine inhibitors of transcription activating proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544732A JP2023544732A (ja) | 2023-10-25 |
| JP2023544732A5 true JP2023544732A5 (https=) | 2024-10-07 |
| JP7777131B2 JP7777131B2 (ja) | 2025-11-27 |
Family
ID=80950900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520101A Active JP7777131B2 (ja) | 2020-10-02 | 2021-09-30 | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12540139B2 (https=) |
| EP (1) | EP4221708A4 (https=) |
| JP (1) | JP7777131B2 (https=) |
| CN (1) | CN116348112A (https=) |
| WO (1) | WO2022072647A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4221708A4 (en) | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| CA3193745A1 (en) | 2020-10-02 | 2022-04-07 | Kang Le | Imidazopiperazine inhibitors of transcription activating proteins |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1537114T3 (da) | 2002-08-07 | 2006-11-13 | Novartis Ag | Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| MX2008015008A (es) | 2006-05-26 | 2008-12-05 | Novartis Ag | INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA. |
| US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008078291A1 (en) | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| CN101686989B (zh) | 2007-06-21 | 2016-10-19 | 卡拉治疗学股份有限公司 | 取代的咪唑并杂环 |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN101468988A (zh) | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN102076694A (zh) | 2008-06-25 | 2011-05-25 | 埃科特莱茵药品有限公司 | 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物 |
| WO2011092120A1 (en) | 2010-01-29 | 2011-08-04 | Nerviano Medical Sciences S.R.L. | 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| CN103087067A (zh) | 2012-08-02 | 2013-05-08 | 盛世泰科生物医药技术(苏州)有限公司 | 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途 |
| US9695176B2 (en) | 2012-10-18 | 2017-07-04 | Bristol-Myers Squibb Company | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| JP6820254B2 (ja) | 2014-10-10 | 2021-01-27 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| EP3632915A1 (en) * | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| EP3445750A4 (en) | 2016-04-18 | 2019-11-27 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| JP7014736B2 (ja) | 2016-05-24 | 2022-02-01 | ジェネンテック， インコーポレイテッド | がんの処置のためのピラゾロピリジン誘導体 |
| EP3464270B1 (en) | 2016-05-24 | 2022-02-23 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer |
| RU2020131507A (ru) | 2018-03-29 | 2022-05-04 | Боард Оф Реджентс, Де Юниверсити Оф Техас Систем | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| CA3193745A1 (en) | 2020-10-02 | 2022-04-07 | Kang Le | Imidazopiperazine inhibitors of transcription activating proteins |
| EP4221708A4 (en) | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
-
2021
- 2021-09-30 EP EP21876483.5A patent/EP4221708A4/en active Pending
- 2021-09-30 CN CN202180068101.0A patent/CN116348112A/zh active Pending
- 2021-09-30 JP JP2023520101A patent/JP7777131B2/ja active Active
- 2021-09-30 WO PCT/US2021/052897 patent/WO2022072647A1/en not_active Ceased
-
2023
- 2023-03-13 US US18/182,614 patent/US12540139B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023544173A5 (https=) | ||
| RU2020131507A (ru) | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции | |
| JP2018515490A5 (https=) | ||
| JP2023544732A5 (https=) | ||
| JP7028996B2 (ja) | 核輸送モジュレーターとしての化合物およびその使用 | |
| JP2019516759A5 (https=) | ||
| CN111770914B (zh) | 作为神经激肽-1受体拮抗剂的化合物及其用途 | |
| KR20210018291A (ko) | 항암 핵 호르몬 수용체-표적화 화합물 | |
| JP6884100B2 (ja) | がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法 | |
| JP2024511996A5 (https=) | ||
| JP2017510641A5 (https=) | ||
| JP2019513743A (ja) | インドールアミン ２，３−ジオキシゲナーゼ阻害剤、その製造方法及び応用 | |
| JP6019126B2 (ja) | 有機ニトロチオエーテル化合物およびその医療用途 | |
| CN121605110A (zh) | 取代杂环化合物及其用途 | |
| JP2021519308A5 (https=) | ||
| JP2009534408A (ja) | Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド | |
| JP2018501287A5 (https=) | ||
| CN111303133A (zh) | 降解ezh2蛋白的小分子化合物 | |
| JP7691974B2 (ja) | アセチル補酵素ａシンテターゼ短鎖２（ａｃｓｓ２）の小分子阻害剤 | |
| JP2016513704A5 (https=) | ||
| WO2023150653A1 (en) | Process for synthesis of quinazoline compounds | |
| US10973828B2 (en) | Biaryl compositions and methods for modulating a kinase cascade | |
| CN106432209A (zh) | Lumacaftor的新晶型及其制备方法 | |
| JP2014005265A5 (https=) | ||
| JP2023544732A (ja) | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |